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Abstract
Background: Current chemotherapy of human cancers focuses on the DNA damage pathway to
induce a p53-mediated cellular response leading to either G1 arrest or apoptosis. However,
genotoxic treatments may induce mutations and translocations that result in secondary
malignancies or recurrent disease. In addition, about 50% of human cancers are associated with
mutations in the p53 gene. Nongenotoxic activation of apoptosis by targeting specific molecular
pathways thus provides an attractive therapeutic approach.
Methods: Normal and leukemic cells were evaluated for their sensitivity to 5, 6-dichloro-1-beta-
D-ribofuranosylbenzimidazole (DRB) through cell viability and caspase activation tests. The
apoptotic pathway induced by DRB was analysed by immunfluorescence and immunoblot analysis.
H2AX phosphorylation and cell cycle analysis were performed to study the dependance of
apoptosis on DNA damage and DNA replication, respectively. To investigate the role of p53 in
DRB-induced apoptosis, specific p53 inhibitors were used. Statistical analysis on cell survival was
performed with the test of independence.
Results: Here we report that DRB, an inhibitor of the transcriptional cyclin-dependent kinases
(CDKs) 7 and 9, triggers DNA replication-independent apoptosis in normal and leukemic human
cells regardless of their p53 status and without inducing DNA damage. Our data indicate that (i) in
p53-competent cells, apoptosis induced by DRB relies on a cytosolic accumulation of p53 and
subsequent Bax activation, (ii) in the absence of p53, it may rely on p73, and (iii) it is independent
of ATM and NBS1 proteins. Notably, even apoptosis-resistant leukemic cells such as Raji were
sensitive to DRB.
Conclusion: Our results indicate that DRB represents a potentially useful cancer
chemotherapeutic strategy that employs both the p53-dependent and -independent apoptotic
pathways without inducing genotoxic stress, thereby decreasing the risk of secondary malignancies.
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Current chemotherapy focuses on the use of genotoxic
drugs. This may induce general DNA damage in cancer
cells but also high levels of toxicity in normal tissues.
Reports over the last 10 years have described new, ther-
apy-related, malignancies whose prognosis is often poor
due to resistance [1-4]. Most cytotoxic drugs, and radio-
therapy, damage tumour cell DNA to induce arrest in G1
or apoptosis [5,6]. However, DNA damage is also induced
in normal cells. It has been shown that alkylating agents
and cisplatin cause unbalanced chromosomal aberrations
[7], and epipodophyllotoxins (inhibitors of topoisomer-
ase II) have been implicated in translocations involving
chromosome bands 11q23 and 21q22, both of which are
associated with secondary malignancies [3,8,9]. In addi-
tion, most chemotherapy treatments rely on induction of
p53-dependent apoptosis. The efficiency of this approach,
however, is diminished by the fact that the p53 gene is
mutated in about 50% of human cancers. Moreover, it is
becoming clear that a high percentage of resistant and
recurrent tumours carry de novo p53 mutations [2,4,6,10].
Nongenotoxic activation of apoptosis by targeting specific
molecular pathways therefore provides an attractive ther-
apeutic strategy in cancers. Inhibition of transcription
induces apoptosis in several cancer cell lines [11,12], and
this apoptosis may be more pronounced in transformed
cells than in their non-transformed counterparts [13].
One class of transcriptional inhibitors comprises the
inhibitors of the CDKs, whose critical role in cell cycle
progression and cellular transcription make them attrac-
tive targets for the elaboration of new anticancer drugs
[14]. A few inhibitors of transcriptional CDKs, including
flavopiridol and seliciclib, are currently providing encour-
aging results in clinical trials, though some pharmacoki-
netic concerns remain to be solved and some aspects of
the biological response they elicit are still undetermined
[14-17]. It is thus of interest to further evaluate the biolog-
ical effects and potential anti-cancer role of inhibitors of
transcriptional CDKs.
DRB is a potent inhibitor of CDK7 and CDK9, kinases that
phosphorylate the COOH-terminal domain (CTD) of the
largest subunit of RNA polymerase II (pol II) [18,19]. It
inhibits more than 50% mRNA synthesis at doses above
40 μM [13,20] and has been shown to inhibit both tran-
scription in vivo [21] and phosphorylation of the pol II
CTD in vitro [18]. Additionally, DRB also inhibits other
protein kinases involved in cellular metabolism such as
casein kinase type I (CK1) and II (CK2) [22]. Blockade of
pol II-dependent transcription, including that elicited by
DRB, had been shown previously to trigger a cell death
signal [11,13,20,23]. The exact underlying mechanisms,
however, are still unclear, particularly with respect to the
question of p53-dependence and the need for ongoing
DNA replication.
In the present study we demonstrate that DRB is highly
cytotoxic regardless of a cell's p53 status and even in the
absence of active DNA synthesis. Prototypic T-, B- and
myelogenous leukaemia cell lines as well as fresh AML
blasts were all susceptible to DRB-induced apoptosis. Our
results suggest that DRB could be an attractive drug for
further evaluation in the treatment of some forms of can-
cer.
Methods
Cell isolation, cell culture and drug treatment
Peripheral blood from four healthy donors, one AT and
one NBS patients was collected after signed informed con-
sent. The AT patient was homozygous for a truncating
mutation; the NBS patient was homozygous for the com-
mon 657del5 mutation. PBMC were isolated and T cell
lines, generated as described [24], were maintained by
periodic stimulation with PHA (Gibco-Invitrogen, Pais-
ley, UK) and irradiated allogeneic PBMC in complete
RPMI medium (RPMI 1640 added with 1% Kanamycin,
1% Sodium Pyruvate, 1% L-Glutamine, 1% non essential
amino acids, 0,1% β-mercapto-ethanol) (all from Gibco-
Invitrogen), supplemented with 5% human serum (Bio-
Witthaker, Cambrex, Baltimore, MD, USA) and 200 U/ml
recombinant IL2 (from the myeloma producing cell line
IL2-t6, kindly provided by Dr A. Lanzavecchia, IRB, Bell-
inzona, Switzerland). LCLs were generated by transforma-
tion of mononuclear cells with Epstein-Barr virus and
maintained at 37°C in a humidified incubator in the pres-
ence of 5% CO2 in complete RPMI medium supple-
mented with 10% heat-inactivated fetal bovine serum
(Gibco-Invitrogen). The human leukaemia cell lines Jur-
kat and MOLT-4, of lymphoid origin, HL60, of myeloid
origin, and Namalwa and Raji from B-cell Burkitt's lym-
phomas were purchased from the American Type Culture
Collection (Rockville, MD, USA) and grown in complete
RPMI medium supplemented with 10% heat-inactivated
fetal bovine serum (Gibco, Invitrogen). One bone mar-
row acute myeloid leukaemia (AML) sample was collected
at San Luigi's Hospital after signed informed consent.
Mononuclear cells were separated by Ficoll-Paque density
centrifugation (Amersham, GE Healthcare, Buckingham-
shhire, UK). Primary AML cells were kept in complete
RPMI medium supplemented with 10% heat-inactivated
fetal bovine serum (Gibco, Invitrogen). Leukemic blast
cell count in the primary sample was about 60%. TAp63α
transfected 293T cells were kindly provided by Dr M. Lo
Iacono, University of Turin, Italy. The transcription inhib-
itor DRB (Sigma-Aldrich Co., St. Louis, MO, USA) was
used at 10–100 μM. Z-VAD-FMK peptide was obtained
from Promega (Madison, WI, USA) and added at 100 μMPage 2 of 13
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PFT (Sigma-Aldrich Co.) were used at 30 μM and 10 μM,
respectively, and added 20 minutes before DRB. Cultured
T cells were γ-irradiated (2 Gy) using a 6 MV accelerator
(Elekta) at a dose of 2 Gy/min. ActD supplied by Sigma-
Aldrich Co. was used at the dose of 0.05 μg/ml.
Flow cytometry
The cell viability was determined by PI (Sigma-Aldrich
Co.) staining; PI was used at the final concentration of 1
μg/ml and incubated at room temperature for 15 min in
the dark before the analysis. Cell survival was expressed
after normalization to medium supplemented with the
drug's solvent ("medium" in the graphs) and shown as
mean ± S.D Caspase activation was analyzed with anti-
Active Caspase-3 (BD PharMingen, San Diego, CA, USA)
as primary antibody and a PE-conjugated goat anti-rabbit
(BD PharMingen) as secondary antibody and using the
Cytofix/Cytoperm Kit (BD PharMingen). Annexin V-FITC
(BD PharMingen) and PI staining was performed in
accordance with the manufacturer's instructions. CD45
staining was performed with anti- CD45-FITC antibody
(BD PharMingen). Cell cycle analysis was based on DNA
content. Briefly, ethanol-fixed cells were treated with 1 μg/
ml RNaseA (Sigma-Aldrich Co.) and stained with 50 μg/
ml PI. Cells were plotted in a FL2W (width) versus FL2A
(area) dot plot and gated to exclude aggregates; gated cells
were plotted in a FL2A histogram to distinguish the cell
cycle phases. To select circulating lymphocytes within
PBMC, lymphocytes were gated based on the SSC and FSC
parameters. Stained cells were analysed on a FACScan
(Becton Dikinson & Co., San Jose CA, USA). Statistical
analysis on cell survival was performed with the test of
independence.
Immunofluorescence
Approximately 400,000 T cells for each condition were
collected, fixed with 4% paraformaldehyde, permeabi-
lized with 0.5% Triton X-100, and blocked with 6%
bovine serum albumin and 2.5% normal goat serum.
They were stained with anti- phospho-Histone H2AX
(Ser139) (Upstate Biotechnology, Charlottesville, VA,
USA), anti-p53 or anti-BAX (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) specific Abs, and with Alexa 546-
conjugated goat anti-mouse as secondary Ab (Molecular
Probes, Invitrogen). MitoTraker Green FM (Molecular
Probes, Invitrogen) was used at the final concentration of
100 nM. Stained cells were transferred to poly-L-lysine-
coated coverslips and slides were mounted with Mowiol
(Calbiochem, San Diego, CA, USA). Fluorescence images
were obtained with a 510 Carl Zeiss confocal laser micro-
scope using a 63× objective. Optical sections through the
nuclei were captured at 0.5 μm intervals, and images were
obtained by projection of the individual sections. For
H2AX phosphorylation quantitative analysis, foci were
counted by eye until at least 40 cells and 40 foci were
recorded per sample.
Cell extracts and subcellular fractionation
Cells were harvested and washed with PBS, pelleted, and
lysed in Laemmli buffer (0.125 M Tris-HCl [pH 6.8], 5%
SDS) containing as inhibitors 1 mM phenylmethylsulfo-
nyl fluoride, pepstatin (10 μg/ml), aprotinin (100 KIU/
ml), leupeptin (10 μg/ml) and 1 mM sodium orthovana-
date (Na3VO4) (all from Calbiochem). Total lysates were
boiled for 2 min, sonicated, and quantified by the micro-
bicinchoninic acid method (Thermo Scientific, Rockford,
IL, USA). Protein content was checked probing the blots
with either vinculin or β-actin specific Abs. For subcellular
fractionation, 2 × 107 T cells were harvested and washed
with PBS; mitochondrial and cytosolic fractions were iso-
lated with the use of the Mitochondria Isolation Kit for
cultured cells (Thermo Scientific, reagent-based method).
The mitochondrial pellet was lysed in Laemmli buffer,
and the cytosolic supernatant was concentrated with a
Microcon device (size cut-off 10 kDa) (Millipore Corpora-
tion, Bedford, MA, USA). Both fractions were quantified
by the micro-bicinchoninic acid method (Thermo Scien-
tific) before analysis by immunoblotting. Protein content
and purity of the fractions were checked probing the blots
with vinculin and TOM40 specific Abs.
Immunoblot analysis
40 μg of total lysates and 20 μg of mitochondrial and
cytosolic fractions were size fractionated by SDS-PAGE 7
to 10% gels and electroblotted onto polyvinylidene diflu-
oride membranes (Amersham, GE Healthcare). After
blocking with 5% non-fat dried milk in PBS plus 0.1%
Tween (Sigma-Aldrich Co.), the membranes were incu-
bated with anti -p53 (YLEM, Avezzano, Italy) or -p53-
pSer15 (Cell Signaling Technology, Danvers, MA, USA.), -
MDM2, -BAX, -TOM40, -p73 (Santa Cruz Biotechnology),
-p63 (Biomeda, Foster City, CA, USA), -vinculin, -β-actin
(Sigma-Aldrich Co.) specific Abs and subsequently with
peroxidase-conjugated secondary antibodies (Amersham,
GE Healthcare). The immunoreactive bands were visual-
ized by ECL Super Signal (Thermo Scientific) on autoradi-
ographic films. Autoradiographic bands were scanned
and quantified by Kodak 1D Image Analysis Software.
Results
The stress response elicited by DRB in human lymphocytes 
results in DNA replication-independent, DNA damage-
independent and p53-mediated apoptosis
We investigated the effects induced by DRB in human
cells. To define the sensitivity of cultured T lymphocytes to
this drug, we assessed the viability of treated cells in a
dose-response experiment using propidium iodide (PI)
staining and flow cytometry. T lymphocytes were suscep-
tible to DRB-induced death within the 40–100 μM rangePage 3 of 13
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h with 100 μM DRB) (Figure 1A). The death mechanism
was apoptosis, as both annexin V+PI- (i.e. early apoptotic
cells, mean 76% at 24 hr with 100 μM DRB) and active
caspase-3+ cells (mean 86% at 24 hr with 100 μM DRB)
could readily be detected (Figure 1B–C). Analogous
results were obtained with proliferating lymphoblastoid B
cell lines (LCLs) (mean 10% viable cells at 72 hr with 100
μM DRB) and with freshly extracted circulating lym-
phocytes (mean 10% viable cells at 72 hr with 100 μM
DRB) (Figure 1A–C). All cell lines showed significant sen-
sitivity to DRB (p < 0.05 with the test of independence) at
doses above 40 μM, compared to untreated cells.
Many agents that block pol II elongation also block DNA
replication. To rule out the possibility that apoptosis was
induced exclusively upon entry of the cells into S phase,
we determined the cell cycle profile of freshly extracted
circulating lymphocytes, virtually all in the G0/G1 phase,
at different time points after DRB treatment, and found
that apoptosis occurred without passage through the S
phase (Figure 2A). Comparable results were obtained
with quiescent cultured T lymphocytes (data not shown).
To verify that DRB induced apoptosis was not attributable
to induction of DNA damage, we assessed phosphoryla-
tion of the histone variant H2AX on serine 139 (γH2AX),
an early and specific indicator of DNA double-strand
breaks (DSBs) [25], by immunofluorescence and confocal
microscopy. As apoptosis itself results in oligonucleo-
somal fragmentation of DNA and H2AX phosphorylation
[26], these experiments were done in the presence of the
caspase inhibitor ZVAD-FMK. Untreated cells displayed
virtually no γH2AX foci (mean 0,83 ± 2,13 foci/cell); after
DRB treatment γH2AX foci formation did not occur
(mean 0,87 ± 2,01 foci/cell) (Figure 2B).
We then investigated the molecular pathway elicited by
DRB in T lymphocytes. As shown in figure 2C, DRB rap-
idly stabilized p53, while phosphorylation of p53 at Ser15
was only detectable when p53 accumulation had already
reached the high level. As phosphorylation of Ser15 on
p53 is synonymous with the activation of DNA damage-
dependent pathways in response to cellular insults [27],
this provides further proof that no genotoxic stress is
imposed on cells treated with DRB. p53 accumulation was
not contrasted by Mdm2, a p53 target required for p53
degradation [28], as this protein was rapidly down regu-
lated, possibly due to the known transcriptional inhibi-
tory effect of DRB (Figure 2C).
Overall, these results indicate that the stress response elic-
ited by DRB in human T cells results in replication- and
DNA-damage-independent apoptosis. They also suggest
that the death pathway thus induced is p53-mediated.
Cytosolic p53 accumulates in pre-apoptotic DRB-treated 
T lymphocytes and correlates with Bax activation
In the light of DRB's potent inhibition of transcription
[13,18,20,21], we reasoned that the apoptotic pathway it
induced did not rely on the transactivation activity of p53.
Recent studies have linked the non-transcriptional pro-
apoptotic activity of p53 to its cytosolic or mitochondrial
localization [29,30]. To determine whether this activity
contributes to DRB-induced apoptosis in human T cells,
we monitored the p53 location of DRB-treated cells. We
first analyzed p53 distribution by immunostaining and
confocal microscopy. A time-course experiment shown
that active caspase-3 becomes detectable 9 hr after DRB
treatment (data not shown), indicating that the signals
which initialize the apoptotic cascade must occur earlier.
We therefore performed p53 confocal microscopy analy-
sis of T lymphocytes harvested at 6 hr from treatment and
DRB induces apoptotic death in T cell lines, LCLs and circu-lating lymphocytesFigure 1
DRB induces apoptotic death in T cell lines, LCLs and 
circulating lymphocytes. (A) DRB induces lymphocytes 
death. Cultured T cells from four donors (left), LCLs from 
three donors (middle) and circulating lymphocytes from 
three donors (right) were kept in medium alone or contain-
ing 10–100 μM DRB, harvested at 24, 48 and 72 hr and ana-
lysed by flow cytometry after stainig with PI. (B) DRB 
treatment induces translocation of phosphatidylserine to the 
external leaflet of the cell membrane. Cultured T cells from 
two donors (black bars), circulating lymphocytes from two 
donors (white bars) and LCLs from two donors (grey bars) 
were kept for 24 hr in medium alone or containing 10–100 
μM DRB, harvested and stained with annexin V and PI. Per-
centages of PI- annexin V+ cells are indicated (mean ± S.D.). 
(C) DRB treatment induces caspase activation. Cultured T 
cells from four donors (black bars) and circulating lym-
phocytes from three donors (white bars) were kept for 24 hr 
in medium alone or containing 10–100 μM DRB, harvested 
and stained with anti-active caspase-3 antibody. Histograms 
show the percentage of active caspase-3+ cells (mean ± S.D.).Page 4 of 13
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preferentially accumulated in the cytosol (Figure 3A). We
then prepared cytosolic and mitochondrial fractions of T
lymphocytes harvested at 1–3–6 hr from treatment, and
determined the distribution of p53 with respect to its
mitochondrial location. Purity of the fractions was
checked by probing the blots for vinculin and TOM40 as
markers for the cytosolic and mitochondrial compart-
ments, respectively (Figure 3B). Results clearly demon-
strated the presence of extranuclear p53 soon after DRB
treatment; it was present in both the cytosolic and the
mitochondrial fractions, and primarily unphosphorylated
on Ser15 (Figure 3B).
Cytosolic accumulation of p53 has been reported to
directly activate Bax to insert and oligomerize into the
mitochondrial membrane, thus leading to the cascade of
mitochondria-mediated apoptosis and caspase-3 activa-
tion [29]. We therefore investigated whether intrinsically
generated high cytosolic p53 levels in DRB-treated cells
were coupled to activation of Bax. We monitored Bax dis-
tribution by immunofluorescence and confocal micros-
copy. In untreated cells Bax appeared in a basal cytosolic
distribution (Figure 3C), whereas 6 hr after DRB treat-
ment a dot-like pattern was displayed by about 20% of
cells and then by virtually 100% after 15 hr (Figure 3C and
data not shown). To better evaluate Bax activation, we
studied the distribution of endogenous Bax with respect
to its mitochondrial localization by fractionation experi-
ments. Results demonstrated that in untreated cells Bax
was free in the cytosol, whereas during DRB treatment it
progressively translocated to the mithocondria, where it
was retained throughout the entire time-course (Figure
3B).
To further investigate the role of mitochondrial p53 in
DRB-induced apoptosis we used pharmacological manip-
ulations to distinguish nuclear and mitochondrial p53
functions. T cells were preincubated with two inhibitors of
p53 that have different mechanisms of action: α-pifithrin
(α-PFT) reversibly blocks the p53-mediated transactiva-
tion of p53-dependent responsive genes [31]; μ-pifithrin
(μ-PFT) blocks the interaction of p53 with Bcl-xL and Bcl-
2 and selectively inhibits p53 translocation to the mito-
chondria, without affecting the transactivation function of
p53 at the level of the genome [32].
While the viability level of DRB-treated T cells did not
change in the presence of α-PFT, preincubation with μ-
PFT conferred partial resistance toward DRB induced
death, with viability at 24 hours of 70% (p < 0,005 com-
pared to DRB alone) (Figure 3D). To assess whether the
blockage of mitochondrial p53 does increase viability
through apoptosis inhibition we analysed caspase-3 acti-
vation in control T cells treated with DRB, either alone or
in the presence of the two p53 inhibitors. We found that
DRB-induced apoptosis is replication-independent, DNA damage-independent and p53-mediatedFigur  2
DRB-induced apoptosis is replication-independent, 
DNA damage-independent and p53-mediated. (A) 
DRB treatment does not induce entry into S phase. Circulat-
ing lymphocytes from one healthy donor were maintained in 
medium alone or containing 100 μM DRB, harvested 3, 6, 9, 
24 and 48 hr after treatment, fixed and analysed for cell 
cycle. Histograms show the percentage of cells in subG0/G1 
(white bars), in G0/G1 (black bars) or in S-G2/M (grey bars) 
phases of the cell cycle at each treatment time. (B) DRB 
treatment does not induce DSBs. Cultured T cells from one 
donor were maintained in medium alone, supplemented with 
the caspase inhibitor ZVAD or supplemented with 100 μM 
DRB and ZVAD. Part of the cells kept in medium alone were 
irradiated with 2 Gy γ-IR. Cells were harvested 24 hr after 
100 μM DRB or 1 hr after 2 Gy γ-IR and stained for γ-H2AX. 
One representative experiment out of two is shown. (C) 
Immunoblot analysis of p53, p53pSer15 and Mdm2 following 
DRB. Time course analysis of normal T cells harvested 
before (0) or at various times after 100 μM DRB treatment. 
One representative experiment out of three is shown.Page 5 of 13
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about 50% as compared to DRB alone (p < 0,05 compared
to DRB alone) (Figure 3E). As expected, α-PFT treatment
had no effect on caspase-3 activation.
These results indicate that DRB leads to p53 accumulation
mainly in the mitochondria and cytosol, without induc-
ing DNA damage. They also suggest that p53 induces Bax
activation and this may be an initiation step of DRB-
induced apoptosis.
DRB-induced apoptosis is independent of ATM and NBS1
T cells from Ataxia-Telangiectasia (AT) and Nijmegen
Breakage Syndrome (NBS) patients are resistant to the
p53-dependent apoptosis induced by DNA intercalating
agents like Actinomycin D [33] and display a clear p53
accumulation defect following genotoxic stimuli such as
ionizing radiation (IR) (Figure 4A). However, DRB-
induced p53 accumulation was comparable to that of nor-
mal cells, as assessed by both western blot analysis and
confocal microscopy (Figure 4A and 4B). As in normal T
lymphocytes, accumulated p53 was essentially cytosolic
(Figure 4B), and assessment of their Bax distribution
revealed a dot-like pattern after DRB treatment, at levels
comparable to the control cells (Figure 4C). Accordingly,
AT and NBS T lymphocytes readily died after DRB treat-
ment, with caspase-3 activation comparable to that of
control T lymphocytes (Figure 4D). These results suggest
that DRB-induced accumulation of p53 and subsequent
apoptosis are ATM- and NBS1-independent.
In the absence of p53, DRB-induced apoptosis is mediated 
by p73
T-cell leukaemia Jurkat cell line lacks p53 protein, perhaps
as the outcome of missense heterozygous point-muta-
tions in the p53 gene [34,35]. It was therefore of interest
to see whether Jurkat T cells undergo apoptosis following
DRB treatment. Western blot analysis confirmed that p53
was not expressed in our Jurkat T cells, not even following
a genotoxic treatment (2 Gy IR) known to induce high lev-
els of p53 (Figure 5A). Nevertheless, they readily died after
DRB in a dose-dependent manner (mean 20% viable cells
at 72 hr with 100 μM DRB) (Figure 5B) and both active
caspase-3 and surface annexin V expression were detected
after treatment, though in a slightly smaller percentage of
cells compared to control T lymphocytes (mean 48% and
52% of positive cells, respectively, at 24 hr with 100 μM
DRB) (Figure 5C). Thus, DRB-induced apoptosis in these
cells occurs despite the absence of p53.
To determine which alternative molecular pathway is
induced by DRB in the absence of p53, we performed
immunoblot analysis in Jurkat T cells for two p53 family
members known to be involved in apoptosis, p63 and
p73 [36]. As shown in figure 5D, the p73 content
increased significantly in the total cell lysates within 1 hr
of exposure to 100 μM DRB and remained upregulated
throughout the time-course, whereas p63 protein was
never detectable.
To further demonstrate the p73-mediated alternative
pathway we pharmacologically inhibited p53 activity in
the MOLT-4 p53 wild type leukemic cell line [37] and
compared p73 induction with and without p53 blockage.
In the absence of p53 inhibition, immunoblot analysis
showed that DRB induced early p53 accumulation, com-
parable to that of normal T cells, and p73 content only
minimally increased. When MOLT-4 cells were preincu-
bated with the two p53 inhibitors, α-PFT and μ-PFT, p53
DRB-induced apoptosis is mediated by cytosolic p53 accumu-lation and Bax activationFigure 3
DRB-induced apoptosis is mediated by cytosolic p53 
accumulation and Bax activation. (A) Confocal analysis 
of p53 localization. Control T cells were harvested before or 
6 hr after 100 μM DRB treatment and stained for p53 and 
with green MitoTraker as cytosolic marker. One representa-
tive experiment out of three is shown. (B) Immunoblot anal-
ysis of p53, p53pSer15 and Bax localization. Time course 
analysis of cytosolic and mitochondrial fractions on control T 
cells after 100 μM DRB treatment. One representative 
experiment out of two is shown. Positive control (+ lane): 
whole cell lysate from a control T cell line treated for 6 hr 
with 0,05 μg/ml ActD. (C) Confocal analysis of Bax distribu-
tion. Control T cells were harvested before or 6 hr after 100 
μM DRB and stained for Bax and with green MitoTraker as 
cytosolic marker. One representative experiment out of 
three is shown. (D) Survival analysis of DRB-treated T cells 
after p53 inhibition. Control T cells were treated with either 
α-PFT or μ-PFT alone or with 100 μM DRB and analyzed at 
24 hr by flow cytometry after stainig with PI and (E) with 
anti-active caspase-3 antibody. Data are normalized to cas-
pase activation with DRB alone (mean ± S.D.).Page 6 of 13
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nificantly at later time points (Figure 5E).
These data suggest that DRB induces a redundant death
pathway and that apoptosis may rely on p73 activation in
the absence of p53.
Prototypic T, B and myelogenous leukaemia/lymphomas 
are susceptible to DRB-induced apoptosis irrespective of 
their p53 status
Having shown that the Jurkat line is sensitive to DRB-
induced apoptosis, we examined DRB's effects on cultured
HL60 cells, a model of acute myelogenous leukaemia, and
on Namalwa and Raji cells, two model Burkitt's lym-
phoma lines.
In HL60 cells p53 gene underwent major deletions, so
these cells completely lack p53 mRNA and protein [38]
(and our data not shown). Nevertheless, they were highly
susceptible to DRB-induced death within the 40–100 μM
range (mean 4% viable cells at 72 hr with 100 μM DRB)
(Figure 6A) and both active caspase-3 and surface annexin
V expression were detected after treatment, though in a
slightly smaller percentage of cells compared to control T
DRB-induced apoptosis is independent of ATM and NBS1Figure 4
DRB-induced apoptosis is independent of ATM and 
NBS1. (A) Immunoblot analysis of p53 and p53pSer15 in AT 
and NBS cells. Time course analysis of whole cell lysates of 
cultured T cells from one control, one AT and one NBS 
patient harvested before (0) or after either 2 Gy γ-IR or 100 
μM DRB treatment. One representative experiment out of 
three is shown. (B, C) Confocal analysis of p53 and Bax local-
ization. Cultured T lymphocytes from one AT and one NBS 
patient were harvested before or 6 hr after 100 μM DRB and 
stained for either p53 or Bax with green MitoTraker as cyt-
solic marker. One representative experiment out of two is 
shown. (D) AT and NBS cell survival and caspase activation 
following DRB treatment. Left panel: cultured T cells from 
one AT, one NBS patient and four controls were kept in 
medium alone or containing 100 μM DRB, harvested at 24, 
48 and 72 hr and analyzed by flow cytometry after staining 
with PI. Right panel: cultured T cells from one AT (black 
bars) and one NBS (white bars) patient were kept for 24 hr 
in medium alone or containing different concentrations of 
DRB, then harvested and stained with anti-active caspase-3 
antibody. Histograms show the percentage of active caspase-
3+ cells.
In the absence of p53, DRB-induced apoptosis is mediated by p73Figure 5
In the absence of p53, DRB-induced apoptosis is 
mediated by p73. (A) Analysis of p53 on Jurkat cells. West-
ern blot analysis was performed on control and Jurkat T cells 
harvested before or 3 hr after 2 Gy γ-IR. (B) DRB induces 
Jurkat cell death. Jurkat cells were kept in medium alone or 
containing 10–100 μM DRB, harvested at 24, 48 and 72 hr 
and analyzed by flow cytometry after staining with PI. p < 
0.05 with the test of independence at doses above 40 μM, 
compared to untreated cells. (C) DRB induces Jurkat apopto-
sis. Jurkat cells were harvested before or 24 hr after 10–100 
μM DRB and stained with anti-active caspase-3 antibody (left 
panel) and with annexin V and PI (right panel). Histograms 
show the percentage of active caspase-3+ cells (mean ± S.D.) 
and PI- annexin V+ cells. (D) Immunoblot analysis of p73 and 
p63 on Jurkat cells harvested before (0) or after 100 μM 
DRB. p73 and p63 positive controls (+ lane): whole cell 
lysate from HL60 and TAp63α transfected 293T cells, 
respectively. (E) Inhibition of p53 in the p53 wild-type 
tumour cell line MOLT-4 induces p73 activation. Western 
blot analysis of MOLT-4 cells harvested before (0) or after 
100 μM DRB alone (left panel) or following preincubation 
with α-PFT and μ-PFT (right panel).Page 7 of 13
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respectively, at 24 hr with 100 μM DRB) (Figure 6B). It is
noticeable that HL60 cells were more sensitive at 24 h
than control cells.
The Namalwa and Raji lines are mutant for p53: Namalwa
cells are p53 double-mutant cells that contain two non-
synonymous mutations in exon 7 of p53 gene, while Raji
cells contain mutations in exon 6 [39]. Nevertheless, the
mutated proteins are stabilized in these cells and can accu-
mulate to relatively high levels [39] (and our data not
shown). As shown in Figure 6C, Namalwa cells were
highly susceptible to DRB-induced death within the 40–
100 μM range in a dose-dependent manner (mean 11%
viable cells at 72 hr with 100 μM DRB) and the death
mechanism was apoptosis, as demonstrated by their pos-
itive staining for active caspase-3 and cell surface annexin
V expression (mean 75% and 63% of positive cells,
respectively, at 24 hr with 100 μM DRB) (Figure 6D). It is
noticeable that Namalwa cells were more sensitive at 24 h
than control cells. Raji cells were also susceptible to DRB-
induced cytotoxicity, albeit with some differences in the
death pathway and kinetics: DRB-induced death occurred
only after 48 hr (Figure 6E) and apoptosis was not the
solely mechanism of death, as caspase-3 activation and
cell surface annexin V expression were only detectable
after 48 hr and in a low percentage of cells (18% and 27%
of positive cells, respectively, at 48 hr with 100 μM DRB)
(Figure 6E).
Blast cells from a primary AML sample are highly sensitive 
to DRB treatment
Lastly, the effect of DRB on cell viability and apoptosis
induction was studied in a human primary AML sample.
Leukemic blasts, selected through SSC/CD45 parameters
[40] accounted for about 60% of total cells. To define the
sensitivity of both tumour blasts and non-malignant cells
to this drug, we assessed the viability of treated cells in a
dose-response experiment using CD45/PI staining and
flow cytometry. Blast cells were susceptible to DRB-
induced death within the 10–100 μM range in a dose-
dependent manner (mean 3% viable cells at 72 h with =
60 μM DRB; p < 0.005 with the test of independence at all
doses, compared to untreated cells) (Figure 7A and data
not shown) and the death mechanism was apoptosis (Fig-
ure 7B). Interestingly, blast cells were significantly more
sensitive to DRB than non-malignant cells at all doses
analysed (p < 0.005 with the test of independence).
Discussion
Here we show that the cyclin-dependent kinase inhibitor
DRB efficiently leads normal and leukemic cells to apop-
tosis in a DNA replication- and DNA damage-independ-
ent manner. In T cells expressing wild type p53, DRB
induced a cytosolic p53 response that led the cells to
apoptosis through Bax activation. Nevertheless, apoptosis
was also induced in p53 deficient/mutated leukemic cells
through alternative pathways, possibly involving p73.
Overall, the transcription stress response imposed by DRB
is very powerful in inducing apoptosis independently of a
cell's p53 status, and could provide an attractive approach
to the treatment of some forms of cancer.
Sensitivity to DRB-induced apoptosis in prototypic leukae-mia/lymphoma cell linesFigure 6
Sensitivity to DRB-induced apoptosis in prototypic 
leukaemia/lymphoma cell lines. (A) DRB induces HL60 
cell death. HL60 cells were cultured in medium alone or con-
taining 10–100 μM DRB, harvested at 24, 48 and 72 hr and 
analysed by flow cytometry after staining with PI. p < 0.005 
with the test of independence at doses above 40 μM, com-
pared to untreated cells. (B) DRB induces HL60 caspase acti-
vation and translocation of phosphatidylserine to the 
external leaflet of the cell membrane. Left panel: HL60 cells 
were kept for 24 hr in medium alone or containing 10–100 
μM DRB, then harvested and stained with anti-active cas-
pase-3 antibody. Histograms show the percentage of active 
caspase-3+ cells (mean ± S.D. of two independent experi-
ments). Right panel: HL60 cells were kept for 24 hr in 
medium alone or containing 10–100 μM DRB, harvested and 
stained with annexin V and PI. Percentages of PI- annexin V+ 
cells are indicated. (C, D) The same experiments were per-
formed on Namalwa cells. (E, F) The same experiments were 
performed on Raji cells, analysing caspase activation and 
translocation of phosphatidylserine to the external leaflet of 
the cell membrane 48 hr after treatment.Page 8 of 13
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Sensitivity to DRB-induced apoptosis in primary AML sampleFigure 7
Sensitivity to DRB-induced apoptosis in primary AML sample. (A) Differential effect of DRB against tumour versus 
non-malignant cells. Total nucleated cells separated from the bone marrow of an AML patient were kept in medium alone or 
containing 10–60 μM DRB, harvested at 24, 48 and 72 hr and analysed by flow cytometry after stainig with anti-CD45 antibody 
and PI. Blast cells (unbroken line) were selected based on CD45/SSC parameters. Non-malignant cells (broken line) were 
selected by exclusion of blast cells and debris. Viability of tumour versus non-malignant cells differed in a statistically significant 
way (p < 0.005 with the test of independence at all doses analysed). (B) DRB treatment induces apoptosis in primary AML cells. 
Left panel: AML cells were kept for 24 hr in medium alone or containing 10–100 μM DRB, harvested and stained with anti-
active caspase-3 antibody (left panel) or annexin V and PI (right panel). Histograms show the percentage of active caspase-3+ 
cells (mean ± S.D. of two independent experiments) and PI- annexin V+ cells.
BMC Cancer 2009, 9:281 http://www.biomedcentral.com/1471-2407/9/281Agents such as DRB that circumvent p53-mediated apop-
tosis and are not associated with DNA damage may prove
valuable in the chemotherapy of both p53-wild type and
p53-mutated tumours, with a decreased risk of therapy-
related, secondary malignancies. Here we show that pro-
totypic T-, B- and myelogenous leukaemia/lymphomas
are all susceptible to DRB-induced death irrespective of
their p53 status. Raji cells, which were used as a prototypic
example of a chemoresistant Burkitt's lymphoma-derived
line [41] that cannot be led to apoptosis by C2-ceramide
or other antitumour agents, such as doxorubicin and
etoposide [42,43], were efficiently induced to die by DRB.
Moreover, the induction of apoptosis in non-proliferative
G0/G1 cells inherent in DRB's activity is a very attractive
attribute, as quiescence is the major feature of the resistant
cells that follow exposure to current chemotherapy.
Finally, the evidence obtained in one AML patient of a dif-
ferential effect of DRB against tumour versus non-malig-
nant cells might suggest that drug toxicity could be
minimized by carefully determining the minimal effective
dose.
It has been suggested that pol II inhibitors may also prove
useful in the treatment of tumours with changes in DNA
repair capacity [44-46] and patients with chronic DNA
repair deficiency syndromes such as AT and NBS, xero-
derma pigmentosum and Cockayne syndrome [3] for
which genotoxic treatments are strongly discouraged. The
present study demonstrates that the apoptotic pathway
induced by DRB is independent of ATM and NBS1,
namely the proteins defective in AT and the NBS, respec-
tively. Thus tumours arising in these patients might be
efficiently and safely treated with DRB. Moreover, ATM is
frequently inactivated in sporadic cancers, particularly
lymphoid malignancies [47]. Here, too, DRB could con-
stitute a very convenient therapeutic option.
It could be interesting to evaluate DRB for possible clini-
cal applications. In comparison to other CDK inhibitors
already in clinical trials, including flavopiridol and selici-
clib, DRB remains one of the most CDK9-selective inhib-
itors [48]. CDK9 is the kinase with the most specific
function limited to regulation of transcription; this selec-
tivity confers the ability to inhibit pol II phosphorylation
rather than cell cycle CDKs or other kinases and to target
noncycling cancer cells. Moreover, differently from fla-
vopiridol that may intercalate into the DNA thereby dam-
aging it [49], DRB does not induce DNA damage.
Relatively high concentrations of DRB have been used in
this work. These could perhaps be reduced by combina-
tion with other drugs if DRB were to be proposed for
chemotherapy, since combination of CDK inhibitors,
including DRB, with the Mdm2 antagonist, nutlin-3a,
leads to the synergistic activation of the cytotoxic p53
functions and allows reduction of the concentrations of
both drugs [50]. Similar combinations could be suggested
to enhance the p53-independent pathways. For example,
p53-independent induction of p21Waf1/Cip1 characteris-
tic of histone deacetylase inhibitors [51] resulted into
enhanced cytotoxicity when combined with CDK inhibi-
tors [52,53].
Blockade of pol II-dependent transcription triggers a cell
death signal [11,13,20,23], though the exact underlying
mechanisms were unclear, particularly with respect to its
p53-dependence and the need for ongoing DNA replica-
tion. Inhibition of pol II (by α-amanitin treatment, RNAi
approach, and high dose UV irradiation) has been found
to induce p53-dependent apoptosis associated with trans-
location of p53 to mitochondria, but only upon entry of
cells into S phase [11,54] or without entry into S phase,
yet in a p53-independent way [13]. Our data help to clar-
ify these issues since we show that in p53-competent cells
induction of a transcription-independent cytosolic func-
tion of p53 and subsequent Bax activation are the driving
forces of DRB-induced apoptosis. This is in accordance
with recent data suggesting that blockade of pol II-medi-
ated transcription induced p53 accumulation, and that
this is critical for eliciting p53-dependent but transcrip-
tion-independent apoptosis [54,55]. However, in the
absence of p53 DRB efficiently elicits apoptosis through
an alternative route that may rely on p73 (see below). We
also demonstrate that DRB-induced apoptosis occurs in
G0/G1 cells, without entering into S phase and is thus free
from significant DNA replication, and that p53 accumula-
tion and susequent apoptosis are independent of possible
DNA damage as already reported [20,54]. Our data thus
yield new insights into the mechanism of cell death
induced by transcriptional blockade.
Some authors have found that inhibition of pol II by
inhibitors of the phosphorylation of the pol II CTD,
including DRB, resulted in the nuclear accumulation of
p53 without concomitant phosphorylation of the Ser15
site of p53 [56,57]. Thus a question was raised as to how
p53 was able to accumulate in the nucleus without Ser15
phosphorylation, this being the modification known to
maintain p53 in the nuclear fraction. While confirming
that the initial accumulation of p53 induced by DRB is
not accompanied by Ser15 phosphorylation, our time
course determination of p53 localization in normal T cells
now clearly shows that p53 is not preferentially accumu-
lated in the nucleus following DRB treatment. Indeed, it is
both strongly and rapidly accumulated in their cytosol, as
shown by both confocal microscopy analysis and fraction-
ation experiments followed by immunoblotting. As previ-
ously described [56], although the initial incubation of
p53 is independent of Ser15 phosphorylation, prolonged
incubation with DRB induces a secondary stress responsePage 10 of 13
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clear that the initial accumulation of p53 does not require
Ser15 phosphorylation and is not related to DNA damage.
The Jurkat T-cell line lacks p53 protein. The absence of a
crucial component necessary for the DRB-induced apop-
tosis of normal human T lymphocytes might have sug-
gested that Jurkat cells were insensitive to DRB. Instead,
they proved to be sensitive to DRB and in the present
study we begin to explore the mechanism of cell killing in
the absence of p53. The rapid (within 1 hour) accumula-
tion of p73 upon treatment of Jurkat cells with DRB sug-
gests that this protein replaces p53 in the induction of
apoptosis. p73 is a member of the p53 gene family and has
been implicated in the apoptosis induced by a variety of
chemotherapeutic drugs whose mechanism of action
involves DNA damage [58,59]. Our findings in the Jurkat
cells provide the first suggestion that activation of pro-
apoptotic p73 also couples transcriptional inhibition to
apoptosis in keeping with a recent demonstration of the
ability of p73 to directly induce cytochrome c release from
isolated mitochondria[60]. The role of p73 in mediating
DRB-induced apoptosis in the absence of p53 is further
supported here by the demonstration that chemical inhi-
bition of p53 activity in a p53 wild-type tumour cell line
does induce p73 accumulation.
In our tumour cell lines, and particularly in Raji cells, the
mechanism of cell death was not solely apoptosis. Indeed,
Raji cells have been described to be apoptosis-resistant
due to defects other than p53 mutations, such as impaired
apoptotic signal transduction in the cytoplasm [43]. Since
DRB apparently induces a death response that overcomes
dysregulated apoptosis in these cells, other modes of cell
death may be supported to be involved in the DRB-
induced response. These remain to be determined, but
may include necrosis, mitotic catastrophe and autophagy,
as well as premature senescence [61]. DRB also inhibits
protein kinases involved in cellular metabolism such as
CK1 and CK2 [22]. It is thus possible that cell response
following DRB treatment could be influenced by the con-
comitant inhibition of different kinases.
Conclusion
In conclusion, our results yield new insight into the apop-
totic pathway induced by DRB and suggest that it could be
used to treat some forms of cancer on account of its strik-
ing ability to induce cell death irrespective of p53 status
and without genotoxic stress.
In this paper, we yield new insight into the apoptotic
pathway induced DRB, an inhibitor of the transcriptional
CDKs 7 and 9. Prototypic T-, B- and myelogenous leukae-
mia cell lines as well as fresh AML blasts were all suscepti-
ble to DRB-induced cell death, suggesting that the
transcription stress response imposed by DRB is very pow-
erful in inducing apoptosis independently of a cell's p53
status and without inducing DNA damage, thus providing
an attractive approach to the treatment of some forms of
cancer.
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